Michael has made it very clear, we’re setting us up for TO, he mentions in many presos the new board is made up with individuals that have experience in mergers and acquisition.
I believe once we get a read out of the HEALY trial, the team will start meeting with BP to find the best deal for shareholders. In tandem hopefully we have word on other potential disorders, highlighting the strength of our science.
If no deal is found at that time, we will 100% be sold after any FDA approval, we don’t have the resources to market and sell Monepantel commercially globally.
The longer we go, bar everything going to plan and approval from FDA after Ph2, we’re worth anywhere between $2.5-5B.
DYOR
PAA - General discussions, page-54
-
- There are more pages in this discussion • 49 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add PAA (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
20.0¢ |
Change
0.005(2.56%) |
Mkt cap ! $97.32M | |||
| Open | High | Low | Value | Volume |
| 19.0¢ | 20.0¢ | 19.0¢ | $18.93K | 96.36K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 4 | 202562 | 19.0¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 20.0¢ | 231972 | 4 |
View Market Depth
| Last trade - 15.43pm 07/10/2024 (20 minute delay) ? |
| PAA (ASX) Chart |